$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
FDA授予LP-184治疗胰腺癌的孤儿药资格
2025-10-19 11:44:20
Check Details
Napabuksi主要用于治疗什么疾病?国内上市了吗?
2025-10-19 11:44:20
Check Details
孤儿药Napabuksi获FDA批准上市了吗?怎么购买?
2025-10-19 11:44:20
Check Details
重磅!索托拉西布治疗KRASxa0G12C突变型晚期胰腺癌效果令人鼓舞
2025-10-19 11:44:20
Check Details
索托拉西布对KRAS G12C突变型晚期胰腺癌有疗效
2025-10-19 11:44:20
Check Details
胰腺癌治疗新发现!患者来源的类器官,为治疗选择提供新希望!
2025-10-19 11:44:20
Check Details
肺癌临床治疗的利器,厄洛替尼上市十多年依旧是主力军
2025-10-19 11:44:20
Check Details
瑞博西林的使用方法及副作用看这一篇就够了!
2025-10-19 11:44:20
Check Details
胰腺癌常见的并发症有哪些?
2025-10-19 11:44:20
Check Details
胰腺癌会导致多种并发症
2025-10-19 11:44:20
Check Details
吉西他滨+厄洛替尼常见的不良反应有哪些?
2025-10-19 11:44:20
Check Details
厄洛替尼治疗胰腺癌效果怎么样?
2025-10-19 11:44:20
Check Details
1
2
...
260
261
262
263
264
265
266
...
4162
4163
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Zongertinib for HER2-Mutant NSCLC: First-Line ORR About 76%, Brain Metastases Controlled, Manage Diarrhea and Hepatotoxicity
2
Selpercatinib Traditional Approval for RET Fusion Solid Tumors: Weight-Based Adults, BSA-Based Pediatrics, Monitor Liver, BP, QT
3
Atezolizumab Plus mFOLFOX as Adjuvant Therapy for Stage III dMMR Colon Cancer: ATOMIC DFS HR 0.50
4
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance in HER2-Positive Advanced Breast Cancer: HER2CLIMB-05 Median PFS 24.9 Months
5
Zenocutuzumab (Bizengri) for NRG1 Fusion Solid Tumors: HER2×HER3 Bispecific, 750mg Q2W, NSCLC/Pancreas/Cholangiocarcinoma
6
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
7
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
8
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
9
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
10
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
11
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
12
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks